Immune checkpoint inhibitor‐associated interstitial lung diseases correlate with better prognosis in patients with advanced non‐small‐cell lung cancer
Background Interstitial lung disease (ILD) induced by immune checkpoint inhibitors (ICIs) is a potentially life‐threatening adverse event. The purpose of this study was to evaluate whether the development of immune‐related adverse events (irAEs), especially ILD, was associated with treatment efficac...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-04-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.13364 |
| _version_ | 1818882824170635264 |
|---|---|
| author | Teppei Sugano Masahiro Seike Yoshinobu Saito Takeru Kashiwada Yasuhiro Terasaki Natsuki Takano Kakeru Hisakane Satoshi Takahashi Toru Tanaka Susumu Takeuchi Akihiko Miyanaga Yuji Minegishi Rintaro Noro Kaoru Kubota Akihiko Gemma |
| author_facet | Teppei Sugano Masahiro Seike Yoshinobu Saito Takeru Kashiwada Yasuhiro Terasaki Natsuki Takano Kakeru Hisakane Satoshi Takahashi Toru Tanaka Susumu Takeuchi Akihiko Miyanaga Yuji Minegishi Rintaro Noro Kaoru Kubota Akihiko Gemma |
| author_sort | Teppei Sugano |
| collection | DOAJ |
| description | Background Interstitial lung disease (ILD) induced by immune checkpoint inhibitors (ICIs) is a potentially life‐threatening adverse event. The purpose of this study was to evaluate whether the development of immune‐related adverse events (irAEs), especially ILD, was associated with treatment efficacy and to research the features and risk factors of ILD in advanced non‐small cell lung cancer (NSCLC). Methods Between December 2015 and November 2018, 130 advanced NSCLC patients were treated with nivolumab, pembrolizumab or atezolizumab. The patients were categorized into two groups (irAEs group or non‐irAEs group). Subsequently, we divided the irAEs group into two groups based on the incidence of ILD (ILD group and irAEs‐non‐ILD group). Treatment efficacy and the characteristics of ILD were evaluated. Results A total of 39 (30%) patients developed irAEs. ILD was observed in 16 (12%) patients. Patients with ILD had a higher objective response rate (ORR) compared with irAEs‐non‐ILD patients and non‐irAEs patients (63%, 43% and 22%, respectively). Median progression‐free survival (mPFS) was 15.9 months in ILD patients, 5.4 months in irAEs‐non‐ILD patients and 3.3 months in non‐irAEs patients (log‐rank test, P = 0.033). Pre‐existing interstitial pneumonia (IP) was an independent risk factor for ILD‐induced ICIs (odds ratio [OR] 14.7; 95% confidence interval [CI]: 2.16–99.6, P = 0.006). Conclusions ORR and PFS were significantly better in ILD patients than in irAEs‐non‐ILD and non‐irAEs patients. Pre‐existing history of IP was an independent risk factor for ILD‐induced ICIs. |
| first_indexed | 2024-12-19T15:23:53Z |
| format | Article |
| id | doaj.art-c4954a43c9cb4b7f899d47cbdfb2064b |
| institution | Directory Open Access Journal |
| issn | 1759-7706 1759-7714 |
| language | English |
| last_indexed | 2024-12-19T15:23:53Z |
| publishDate | 2020-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj.art-c4954a43c9cb4b7f899d47cbdfb2064b2022-12-21T20:15:56ZengWileyThoracic Cancer1759-77061759-77142020-04-011141052106010.1111/1759-7714.13364Immune checkpoint inhibitor‐associated interstitial lung diseases correlate with better prognosis in patients with advanced non‐small‐cell lung cancerTeppei Sugano0Masahiro Seike1Yoshinobu Saito2Takeru Kashiwada3Yasuhiro Terasaki4Natsuki Takano5Kakeru Hisakane6Satoshi Takahashi7Toru Tanaka8Susumu Takeuchi9Akihiko Miyanaga10Yuji Minegishi11Rintaro Noro12Kaoru Kubota13Akihiko Gemma14Department of Pulmonary Medicine and Oncology, Graduate School of Medicine Nippon Medical School Tokyo JapanDepartment of Pulmonary Medicine and Oncology, Graduate School of Medicine Nippon Medical School Tokyo JapanDepartment of Pulmonary Medicine and Oncology, Graduate School of Medicine Nippon Medical School Tokyo JapanDepartment of Pulmonary Medicine and Oncology, Graduate School of Medicine Nippon Medical School Tokyo JapanDepartment of Analytic Human Pathology, Graduate School of Medicine Nippon Medical School Tokyo JapanDepartment of Pulmonary Medicine and Oncology, Graduate School of Medicine Nippon Medical School Tokyo JapanDepartment of Pulmonary Medicine and Oncology, Graduate School of Medicine Nippon Medical School Tokyo JapanDepartment of Pulmonary Medicine and Oncology, Graduate School of Medicine Nippon Medical School Tokyo JapanDepartment of Pulmonary Medicine and Oncology, Graduate School of Medicine Nippon Medical School Tokyo JapanDepartment of Pulmonary Medicine and Oncology, Graduate School of Medicine Nippon Medical School Tokyo JapanDepartment of Pulmonary Medicine and Oncology, Graduate School of Medicine Nippon Medical School Tokyo JapanDepartment of Pulmonary Medicine and Oncology, Graduate School of Medicine Nippon Medical School Tokyo JapanDepartment of Pulmonary Medicine and Oncology, Graduate School of Medicine Nippon Medical School Tokyo JapanDepartment of Pulmonary Medicine and Oncology, Graduate School of Medicine Nippon Medical School Tokyo JapanDepartment of Pulmonary Medicine and Oncology, Graduate School of Medicine Nippon Medical School Tokyo JapanBackground Interstitial lung disease (ILD) induced by immune checkpoint inhibitors (ICIs) is a potentially life‐threatening adverse event. The purpose of this study was to evaluate whether the development of immune‐related adverse events (irAEs), especially ILD, was associated with treatment efficacy and to research the features and risk factors of ILD in advanced non‐small cell lung cancer (NSCLC). Methods Between December 2015 and November 2018, 130 advanced NSCLC patients were treated with nivolumab, pembrolizumab or atezolizumab. The patients were categorized into two groups (irAEs group or non‐irAEs group). Subsequently, we divided the irAEs group into two groups based on the incidence of ILD (ILD group and irAEs‐non‐ILD group). Treatment efficacy and the characteristics of ILD were evaluated. Results A total of 39 (30%) patients developed irAEs. ILD was observed in 16 (12%) patients. Patients with ILD had a higher objective response rate (ORR) compared with irAEs‐non‐ILD patients and non‐irAEs patients (63%, 43% and 22%, respectively). Median progression‐free survival (mPFS) was 15.9 months in ILD patients, 5.4 months in irAEs‐non‐ILD patients and 3.3 months in non‐irAEs patients (log‐rank test, P = 0.033). Pre‐existing interstitial pneumonia (IP) was an independent risk factor for ILD‐induced ICIs (odds ratio [OR] 14.7; 95% confidence interval [CI]: 2.16–99.6, P = 0.006). Conclusions ORR and PFS were significantly better in ILD patients than in irAEs‐non‐ILD and non‐irAEs patients. Pre‐existing history of IP was an independent risk factor for ILD‐induced ICIs.https://doi.org/10.1111/1759-7714.13364Immune check inhibitorimmune‐related adverse eventsinterstitial lung diseaseprognosis |
| spellingShingle | Teppei Sugano Masahiro Seike Yoshinobu Saito Takeru Kashiwada Yasuhiro Terasaki Natsuki Takano Kakeru Hisakane Satoshi Takahashi Toru Tanaka Susumu Takeuchi Akihiko Miyanaga Yuji Minegishi Rintaro Noro Kaoru Kubota Akihiko Gemma Immune checkpoint inhibitor‐associated interstitial lung diseases correlate with better prognosis in patients with advanced non‐small‐cell lung cancer Thoracic Cancer Immune check inhibitor immune‐related adverse events interstitial lung disease prognosis |
| title | Immune checkpoint inhibitor‐associated interstitial lung diseases correlate with better prognosis in patients with advanced non‐small‐cell lung cancer |
| title_full | Immune checkpoint inhibitor‐associated interstitial lung diseases correlate with better prognosis in patients with advanced non‐small‐cell lung cancer |
| title_fullStr | Immune checkpoint inhibitor‐associated interstitial lung diseases correlate with better prognosis in patients with advanced non‐small‐cell lung cancer |
| title_full_unstemmed | Immune checkpoint inhibitor‐associated interstitial lung diseases correlate with better prognosis in patients with advanced non‐small‐cell lung cancer |
| title_short | Immune checkpoint inhibitor‐associated interstitial lung diseases correlate with better prognosis in patients with advanced non‐small‐cell lung cancer |
| title_sort | immune checkpoint inhibitor associated interstitial lung diseases correlate with better prognosis in patients with advanced non small cell lung cancer |
| topic | Immune check inhibitor immune‐related adverse events interstitial lung disease prognosis |
| url | https://doi.org/10.1111/1759-7714.13364 |
| work_keys_str_mv | AT teppeisugano immunecheckpointinhibitorassociatedinterstitiallungdiseasescorrelatewithbetterprognosisinpatientswithadvancednonsmallcelllungcancer AT masahiroseike immunecheckpointinhibitorassociatedinterstitiallungdiseasescorrelatewithbetterprognosisinpatientswithadvancednonsmallcelllungcancer AT yoshinobusaito immunecheckpointinhibitorassociatedinterstitiallungdiseasescorrelatewithbetterprognosisinpatientswithadvancednonsmallcelllungcancer AT takerukashiwada immunecheckpointinhibitorassociatedinterstitiallungdiseasescorrelatewithbetterprognosisinpatientswithadvancednonsmallcelllungcancer AT yasuhiroterasaki immunecheckpointinhibitorassociatedinterstitiallungdiseasescorrelatewithbetterprognosisinpatientswithadvancednonsmallcelllungcancer AT natsukitakano immunecheckpointinhibitorassociatedinterstitiallungdiseasescorrelatewithbetterprognosisinpatientswithadvancednonsmallcelllungcancer AT kakeruhisakane immunecheckpointinhibitorassociatedinterstitiallungdiseasescorrelatewithbetterprognosisinpatientswithadvancednonsmallcelllungcancer AT satoshitakahashi immunecheckpointinhibitorassociatedinterstitiallungdiseasescorrelatewithbetterprognosisinpatientswithadvancednonsmallcelllungcancer AT torutanaka immunecheckpointinhibitorassociatedinterstitiallungdiseasescorrelatewithbetterprognosisinpatientswithadvancednonsmallcelllungcancer AT susumutakeuchi immunecheckpointinhibitorassociatedinterstitiallungdiseasescorrelatewithbetterprognosisinpatientswithadvancednonsmallcelllungcancer AT akihikomiyanaga immunecheckpointinhibitorassociatedinterstitiallungdiseasescorrelatewithbetterprognosisinpatientswithadvancednonsmallcelllungcancer AT yujiminegishi immunecheckpointinhibitorassociatedinterstitiallungdiseasescorrelatewithbetterprognosisinpatientswithadvancednonsmallcelllungcancer AT rintaronoro immunecheckpointinhibitorassociatedinterstitiallungdiseasescorrelatewithbetterprognosisinpatientswithadvancednonsmallcelllungcancer AT kaorukubota immunecheckpointinhibitorassociatedinterstitiallungdiseasescorrelatewithbetterprognosisinpatientswithadvancednonsmallcelllungcancer AT akihikogemma immunecheckpointinhibitorassociatedinterstitiallungdiseasescorrelatewithbetterprognosisinpatientswithadvancednonsmallcelllungcancer |